Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics

Barchart · 4d ago

Trading under DCOY to commence on January 8, 2026

Company’s proprietary peptide-conjugate platform leverages AI-enabled computational infrastructure to accelerate candidate selection

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.